Nothing Special   »   [go: up one dir, main page]

DE60231295D1 - R und ppar modulatoren - Google Patents

R und ppar modulatoren

Info

Publication number
DE60231295D1
DE60231295D1 DE60231295T DE60231295T DE60231295D1 DE 60231295 D1 DE60231295 D1 DE 60231295D1 DE 60231295 T DE60231295 T DE 60231295T DE 60231295 T DE60231295 T DE 60231295T DE 60231295 D1 DE60231295 D1 DE 60231295D1
Authority
DE
Germany
Prior art keywords
ppar modulators
ppar
modulators
diabetes
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231295T
Other languages
English (en)
Inventor
Jacqueline C Bussolari
Xiaoli Chen
Bruce R Conway
Keith T Demarest
Hamish N Ross
Rafael Severino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Ortho McNeil Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60231295D1 publication Critical patent/DE60231295D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/305Mercury compounds
    • A61K31/31Mercury compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE60231295T 2001-04-04 2002-04-03 R und ppar modulatoren Expired - Lifetime DE60231295D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04
PCT/US2002/010538 WO2002080936A1 (en) 2001-04-04 2002-04-03 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Publications (1)

Publication Number Publication Date
DE60231295D1 true DE60231295D1 (de) 2009-04-09

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231295T Expired - Lifetime DE60231295D1 (de) 2001-04-04 2002-04-03 R und ppar modulatoren

Country Status (11)

Country Link
US (3) US20030045553A1 (de)
EP (2) EP1381361B1 (de)
JP (1) JP4590159B2 (de)
CN (1) CN100577175C (de)
AT (1) ATE423559T1 (de)
CA (1) CA2442917C (de)
DE (1) DE60231295D1 (de)
ES (1) ES2321815T3 (de)
MY (1) MY180762A (de)
TW (1) TWI330084B (de)
WO (1) WO2002080936A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577175C (zh) 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
ES2331561T3 (es) * 2001-04-04 2010-01-08 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Terapia combinada que comprende inhibidores de la reabsorcion de glucosa y moduladores de receptores de retinoides x.
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (de) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004108126A1 (en) * 2003-06-06 2004-12-16 Snowden Pharmaceuticals, Llc Fibric acid derivatives for the treatment of irritable bowel syndrome
BRPI0412009A (pt) * 2003-06-27 2006-08-15 Reddy Research Foundation composições compreendendo balaglitazona e outros compostos antidiabéticos
JP2007505854A (ja) * 2003-09-23 2007-03-15 ディーエスエム アイピー アセッツ ビー.ブイ. 糖尿病の治療および予防用組成物
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
JPWO2005070413A1 (ja) * 2004-01-23 2007-09-06 独立行政法人科学技術振興機構 レチノイン酸を含有する糖尿病治療薬
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
ES2581331T3 (es) 2004-07-21 2016-09-05 Kissei Pharmaceutical Co., Ltd. Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
EP1853258A4 (de) * 2005-03-03 2008-05-07 Smithkline Beecham Corp Medikamente
JP2009509539A (ja) * 2005-09-30 2009-03-12 パーレジェン サイエンシーズ, インコーポレイテッド 血糖調節の障害のスクリーニングおよび処置のための方法および組成物
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2009005815A1 (en) * 2007-07-05 2009-01-08 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CA2711673A1 (en) * 2008-01-31 2009-08-06 Astellas Pharma Inc. Pharmaceutical compositions for treating fatty liver disease
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
RS52236B (en) * 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
JP5077786B2 (ja) 2009-04-16 2012-11-21 大正製薬株式会社 併用医薬
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
MX2012003400A (es) 2009-10-02 2012-04-10 Sanofi Sa Uso de compuestos con actividad inhibidora de sglt - 1/sglt - 2 para producir medicamentos para el tratamiento de enfermedades oseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
PT2543357T (pt) * 2011-07-07 2018-04-30 Holy Stone Healthcare Co Ltd Resumo
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CA3086828A1 (en) * 2017-12-28 2019-07-04 University Of Fukui Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
US5731292A (en) 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
DE69631541T2 (de) 1995-09-18 2004-12-23 Ligand Pharmaceuticals, Inc., San Diego Behandlung von NIDDM (nicht-insulinabhängigem Diabetes Mellitus)
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP2000514807A (ja) * 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療
DK0850948T3 (da) 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Sabicイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
AU8799998A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
KR100652326B1 (ko) * 1998-11-20 2006-11-29 미쯔비시 가가꾸 가부시끼가이샤 5-[(6-(2-플루오로벤질)옥시-2-나프틸)메틸]-2,4-티아졸리딘디온의 결정체
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4649600A (en) 1999-04-22 2000-11-10 Joel F. Habener Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
RU2232767C2 (ru) 1999-08-31 2004-07-20 Киссеи Фармасьютикал Ко., Лтд. Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения
JP2003508391A (ja) 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TR200402512T4 (tr) * 1999-11-10 2004-12-21 Takeda Chemical Industries, Ltd. Hipoglisemik ve hipolipidemik aktiviteye sahip 5-üyeli N-heterosiklik bileşikler
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
MXPA03003870A (es) 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
IL156678A0 (en) 2000-12-28 2004-01-04 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ES2331561T3 (es) 2001-04-04 2010-01-08 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Terapia combinada que comprende inhibidores de la reabsorcion de glucosa y moduladores de receptores de retinoides x.
CN100577175C (zh) 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法

Also Published As

Publication number Publication date
US20030199557A1 (en) 2003-10-23
JP2004529915A (ja) 2004-09-30
CA2442917C (en) 2011-02-01
EP2065044A1 (de) 2009-06-03
TWI330084B (en) 2010-09-11
MY180762A (en) 2020-12-08
CN100577175C (zh) 2010-01-06
ATE423559T1 (de) 2009-03-15
US20030045553A1 (en) 2003-03-06
US8278268B2 (en) 2012-10-02
CN1568190A (zh) 2005-01-19
US20080096802A1 (en) 2008-04-24
EP1381361B1 (de) 2009-02-25
JP4590159B2 (ja) 2010-12-01
WO2002080936A1 (en) 2002-10-17
ES2321815T3 (es) 2009-06-12
EP1381361A1 (de) 2004-01-21
CA2442917A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
DE60231295D1 (de) R und ppar modulatoren
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
NO20053041D0 (no) Behandling av diabetes.
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60237823D1 (de) Medizinisches behandlungsinstrument
ATE410165T1 (de) Nociceptin-analoga
IL158593A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
NO20022087L (no) Fremgangsmåte for behandling av diabetes
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE451921T1 (de) Phenylindole zur behandlung von hiv
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition